Limits...
Cell or cell membrane-based drug delivery systems.

Tan S, Wu T, Zhang D, Zhang Z - Theranostics (2015)

Bottom Line: Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS.In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles.We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

View Article: PubMed Central - PubMed

Affiliation: 1. Tongji School of Pharmacy; ; 2. National Engineering Research Center for Nanomedicine; ; 3. Hubei Engineering Research Center for Novel DDS, Huazhong University of Science and Technology, Wuhan 430030, P R China.

ABSTRACT
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

No MeSH data available.


Related in: MedlinePlus

Generation of exosome-mimetic nanovesicles (NV) in different ways (a) Schematic illustration of the procedure for the generation of chemotherapeutics-loaded NV. (b) Schematic illustration of microfluidic fabrication of NV. (c) Sectional view of centrifuge device and schematic process of NV generation. Reproduced with permission137-139. Copyright 2014, ACS, RSC.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4440443&req=5

Figure 10: Generation of exosome-mimetic nanovesicles (NV) in different ways (a) Schematic illustration of the procedure for the generation of chemotherapeutics-loaded NV. (b) Schematic illustration of microfluidic fabrication of NV. (c) Sectional view of centrifuge device and schematic process of NV generation. Reproduced with permission137-139. Copyright 2014, ACS, RSC.

Mentions: An obstacle for the development of exosome based DDS is that mammalian cells released relatively low quantities of exosomes (e.g., ~ 0.1 μg protein per 106 DCs) and the purification was a little complicated18, 136. To improve the yield of exosomes, Jang et al developed exosome-mimetic vesicles (U937NV) to deliver chemotherapeutic drug through a series of extruding steps followed by density gradient ultracentrifugation for collection and purification (Figure 10a)137. The yield of DOX-loaded exosome-mimetic vesicles (U937NVDox) was 203 μg of total protein and 210×109 particles per 1×107 U937 cells, which was more than 100-fold of natural produced exosome (U937EXO, only 1.74 μg total protein and 2×109 particles). Moreover, the size, morphology, and protein marker (CD63, Tsg 101 and Moesin) contents of U937NV were almost the same as those of U937EXO. It was also found that U937NVDox had the similar inhibiting ability against tumor growth with U937EXODox. Park's group described the large-scale fabrication methods of NVs via microfluidics or centrifugation device (Figure 10b&c)138, 139. The yield of the resulted NVs was 20.18 μg of total protein per 1.5×106 murine embryonic stem (ES) cells and 952 μg of total protein per 1×108 ES cells, respectively. This may promote the comprehensive research on exosomes based DDS.


Cell or cell membrane-based drug delivery systems.

Tan S, Wu T, Zhang D, Zhang Z - Theranostics (2015)

Generation of exosome-mimetic nanovesicles (NV) in different ways (a) Schematic illustration of the procedure for the generation of chemotherapeutics-loaded NV. (b) Schematic illustration of microfluidic fabrication of NV. (c) Sectional view of centrifuge device and schematic process of NV generation. Reproduced with permission137-139. Copyright 2014, ACS, RSC.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4440443&req=5

Figure 10: Generation of exosome-mimetic nanovesicles (NV) in different ways (a) Schematic illustration of the procedure for the generation of chemotherapeutics-loaded NV. (b) Schematic illustration of microfluidic fabrication of NV. (c) Sectional view of centrifuge device and schematic process of NV generation. Reproduced with permission137-139. Copyright 2014, ACS, RSC.
Mentions: An obstacle for the development of exosome based DDS is that mammalian cells released relatively low quantities of exosomes (e.g., ~ 0.1 μg protein per 106 DCs) and the purification was a little complicated18, 136. To improve the yield of exosomes, Jang et al developed exosome-mimetic vesicles (U937NV) to deliver chemotherapeutic drug through a series of extruding steps followed by density gradient ultracentrifugation for collection and purification (Figure 10a)137. The yield of DOX-loaded exosome-mimetic vesicles (U937NVDox) was 203 μg of total protein and 210×109 particles per 1×107 U937 cells, which was more than 100-fold of natural produced exosome (U937EXO, only 1.74 μg total protein and 2×109 particles). Moreover, the size, morphology, and protein marker (CD63, Tsg 101 and Moesin) contents of U937NV were almost the same as those of U937EXO. It was also found that U937NVDox had the similar inhibiting ability against tumor growth with U937EXODox. Park's group described the large-scale fabrication methods of NVs via microfluidics or centrifugation device (Figure 10b&c)138, 139. The yield of the resulted NVs was 20.18 μg of total protein per 1.5×106 murine embryonic stem (ES) cells and 952 μg of total protein per 1×108 ES cells, respectively. This may promote the comprehensive research on exosomes based DDS.

Bottom Line: Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS.In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles.We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

View Article: PubMed Central - PubMed

Affiliation: 1. Tongji School of Pharmacy; ; 2. National Engineering Research Center for Nanomedicine; ; 3. Hubei Engineering Research Center for Novel DDS, Huazhong University of Science and Technology, Wuhan 430030, P R China.

ABSTRACT
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

No MeSH data available.


Related in: MedlinePlus